Collaboration in Healthcare - Strategic Focus & Partnerships

For us, partnering is a key element in delivering meaningful therapies to patients with unmet medical needs. To complement our company's own R&D efforts, we collaborate with strategic partners to source new compounds, gain access to the latest technology platforms, and develop novel therapeutics for patients.

Our goal is to craft a pipeline that is a mix of both internal and externally-sourced assets that are in line with the company’s growth goals and strategically fit with both commercial and developmental strengths.

Independent from our therapeutic areas of focus, we are consciously agnostic of the source of assets that can enrich our global commercial and regional portfolio. The focus is first and foremost on the quality and potential benefit these assets can bring to patients. We consider all opportunities that have the potential to create value using innovative deal structures and creative alliances.

We are particularly interested in opportunities that will support our strategic business areas.

As an active player in Oncology, we strive to achieve a focused leadership position in selected indications. We are actively searching for and evaluating clinical-stage opportunities to strengthen our clinical pipeline. Priority is given to assets that are in development in our core indications, which include, but are not limited to SCCHN, CRC and urothelial cancers.

For preclinical and early-stage clinical assets, we are actively searching for assets/technologies which can support our Oncology R&D groups with a balanced portfolio of innovative concepts and novel targeting approaches.

Rare Tumors
 
In the Rare Tumors space, we are digging deep into the science and biology of rare tumors to identify promising assets which address the high medical need of patients living with devastating cancers. With our launch assets Ogsiveo in Desmoid Tumors, Gomekli/Ezmekli in neurofibromatosis type 1 and pimitcotinib in TCGT, we are paving the way to bring ground breaking new medicines in underserved rare tumor indications. Novel assets in all clinical stages of development in the rare tumor spaces like sarcomas, myeloproliferative diseases or neurological cancers are of interest to our R&D and commercial franchise organizations.
 
Please contact the BD Oncology & Rare Tumor team for partnership proposals.

Our focus is the development of best-in-disease therapeutics in neurological and immunological diseases, with particular interest in:

• Movement disorders
• Neuromuscular disorders
• Acute CNS such as Acute Ischemic Stroke (AIS) or Traumatic Brain Injury (TBI)
• Peripheral autoimmune diseases such as Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN)
• Agents with the potential to induce immune tolerance/restore immune homeostasis.
  

Pre-PoC Focus
For pre-PoC assets, we are interested in the following MoAs:

• Inflammasome activation
• Autophagy, Lysosome pathway
• Cell Death Mechanisms
• Cellular Stress Response
• Mitochondrial Dysfunction
• Synaptic and axonal dysfunction
  

Post-PoC Focus
For post-PoC assets, we maintain a MoA-agnostic approach.

Modalities
We focus on advanced therapeutic modalities that have demonstrated proof-of-concept (PoC) and show strong differentiation potential. Key areas of interest include:

• Small molecules
• Biologics
• ADCs
• TPDs
• mRNA

For emerging modalities like cell and gene therapies, we focus on post-PoC opportunities with established clinical validation and robust CMC processes.
Please contact the GBD team for partnership proposals.

As a world leader in fertility treatment, we develop and provide innovative products, devices, and support services to assist infertile couples at every stage of the fertility treatment cycle, from follicular development to early pregnancy.

We actively search for and evaluate preclinical and clinical assets and technologies that align with our commitment to innovation and offer clear differentiation potential.

Our search scope includes novel therapies and drug delivery methods for medically assisted reproduction to enhance treatment outcomes both for Female and Male Infertility. Furthermore, we are interested in clinical decision support systems for IVF treatment, and therapies aimed at improving oocyte quality and endometrial receptivity. 

Cardiovascular, Metabolism & Endocrinology

Our purpose is to bring better health to every single cardiometabolic and endocrine patient, helping them to live their life to its full potential. We must address chronic diseases such as diabetes, hypertension, growth hormone disorders or hypothyroidism, in view of their impact on health and society. Through our leading and affordable portfolio, beyond the pill’ solutions and partnerships, we are helping to improve awareness, diagnosis, treatment and adherence of these diseases.

Every day, some 70 million patients across the globe use our trusted medicines like Glucophage® and Glucovance® (Diabetes); Concor® (Cardiovascular); Euthyrox® (Thyroids) or Saizen® (Growth hormone deficiency). Our long-lasting and successful presence in Emerging Markets is based on strong local commercial and medical infrastructure as well as continued investment in our established brands.

We want to fuel additional growth via branded portfolio expansion and meet regional and global commercial needs. We strive to offer patients and physicians products, solutions and services that address unmet medical and patient needs in:

Metabolism:

• Type 2 Diabetes
• Genetic obesity 
• Cong. Hyperinsulinism 
• Other rare metabolic conditions

Cardiovascular: 

• Hypertension
• Heart Failure
• Lipid regulation
• Coronary artery diseases  
• Hypertrophic cardiomyopathy
• Other rare cardiovascular conditions

Thyroids & Endocrinology:

• Hypo/Hyperthyroidism
• Hypoparathyroidism
• Growth hormone regulation (GHD, acromegaly, others)
• Cong. Adrenal hypoplasia
• Other rare endocrine conditions

To support our pre-clinical discovery and development efforts across our therapeutic areas, we search for and evaluate novel technologies in following areas:

Technologies that transfer differentiation, speed and efficiency to our “armed antibody” platforms, incl.

• Next-gen novel payloads beyond tubulin- & Topoisomerase inhibitors
• AOC constructs
• Novel targeting technologies
• Novel linker technologies

Novel delivery technologies allowing for larger therapeutic index and delivery of novel agents (e.g. oligonucleotide moieties) to target organs.

Differentiated degrader technologies allowing for e.g. tissue specificity or tackling difficult to drug targets

Innovative technologies for binder generation in the antibody and degrader context.

Access to large scale multi-omics datasets, HOR and RWD as well as tools for the improvement of clinical development e.g., clinical patient stratification, site selection and clinical trial success predictions

We have dedicated ourselves to improving access to health in underserved populations. We contribute the competencies we have acquired from working at the interface of medicines, chemicals and diagnostics.

For many diseases in question, young children are the most vulnerable age group in need for a suitable treatment. The goal is to develop innovative and integrated health solutions (drugs, diagnostics, medical devices, vector controls and digital health tools) for the most vulnerable populations in developing countries.

We are regularly reviewing our development candidate portfolio and are actively seeking partnerships for assets that we have strategically deprioritized. Such assets are typically in the late stage-preclinical / early-stage clinical development stage.

We are open to discuss partnering proposals with pharma and biotech organizations to license such assets, but are also open to build new companies around such assets with VC/PE investors.

We are seeking to build our presence in New Therapeutic Areas focused on rare diseases in fields with high unmet need and limited competition where there is strong pricing potential. We seek post-proof-of-concept (POC) assets in these areas that have the potential to deliver transformative efficacy potential, and we prefer opportunities that include U.S. rights.

From a modality perspective, our focus is on small molecules, biologics, ADCs, TPDs, and mRNA, but we are open to all modalities. For new modalities such as cell and gene therapies, robust CMC will be of particular importance in addition to POC.

Please contact the Global Business Development team for partnership proposals.

Ensuring our alliances are supported by the right teams with the right resources is a priority for us. Our focus is on:

• Maximizing the value of the alliance for both partners, and reducing the risk of failure
• Resolving issues in advance in the best interest of the projects
• Providing a lead alliance governance structure
• Monitoring whether the legal framework of current alliances still reflect the initial objectives in light of the environmental changes
• New Opportunities: Identifying new opportunities with current partners